ZNF410 and sickle cell disease: Sickle cell disease patient HSPCs that have been treated with a vector containing both a ZNF410 and a BCL11A shRNAmiRs and differentiated into erythrocytes led to an increase of 10% HbF and a significant decrease of sickled cells in comparison to BCL11A shRNAmiR only vector treated cells [70].